Abstrakt

Przypisy

• 1. Belizna C., Henrion D., Beucher A., Lavigne C., Ghaali A., LévesqueH.: Anti-Ku antibodies: clinical, genetic and diagnostic insights. Autoimmun.Rev., 2010; 9: 691-694
  Google Scholar
• 2. Ceribelli A., Cavazzana I., Franceschini F., Airò P., Cattaneo R., PauleyB.A., Chan E.K., Satoh M.: Anti Th/To are common antinucleolarautoantibodies in Italian patients with scleroderma. J. Rheumatol.,2010; 37: 2071-2075
  Google Scholar
• 3. Chung L., Utz P.J.: Antibodies in scleroderma. Direct pathogenicityand phenotypic associations. Curr. Rheumatol. Rep., 2004; 6: 156-163
  Google Scholar
• 4. Faucher B., Stein P., Granel B., Weiller P.J., Disdier P., Serratrice J.,Harlé J.R., Durand J.M., Frances Y., Guis S., Pham T., Bardin N., SanmarcoM.: Low prevalence of anti-RNA polymerase III antibodies in aFrench scleroderma population. Eur. J. Inter. Med., 2010; 21: 114-117
  Google Scholar
• 5. Hachulla E., Launay D.: Diagnosis and classification of systemicsclerosis. Clin. Rev. Allergy Immunol., 2011; 40: 78-83
  Google Scholar
• 6. Hamaguchi Y.: Autoantibody profiles in systemic sclerosis: predictivevalue for clinical evaluation and prognosis. J. Dermatol.,2010; 37: 42-53
  Google Scholar
• 7. Hamdouch K., Rodriguez C., Perez-Venegas J., Rodríguez I., AstolaA., Ortiz M., Yen T.J., Bennani M., Valdivia M.M.: Anti-CENPI autoantibodiesin scleroderma patients with features of autoimmune liverdiseases. Clin. Chim. Acta, 2011; 412: 2267-2271
  Google Scholar
• 8. Hashimoto A., Endo H., Kondo H., Hirohata S.: Clinical featuresof 405 Japanese patients with systemic sclerosis. Mod. Rheumatol.,2012; 22: 272-279
  Google Scholar
• 9. Kuwana M., Okano Y., Pandey J.P., Silver R.M., Fertig N., MedsgerT.A.Jr: Enzyme-linked immunosorbent assay for detection of antiRNApolymerase III antibody: analytical accuracy and clinical associationsin systemic sclerosis. Arthritis Rheum., 2005; 52: 2425-2432
  Google Scholar
• 10. LeRoy E.C., Black C., Fleischmajer R., Jablonska S., Krieg T., MedsgerT.A. Jr, Rowell N., Wollheim F.: Scleroderma (systemic sclerosis):classification, subsets and pathogenesis. J. Rheumatol., 1988;15: 202-204
  Google Scholar
• 11. Maes L., Blockmans D., Verschueren P., Westhovens R., De BeéckK.O., Vermeersch P., Van den Bergh K., Burlingame R.W., Mahler M.,Bossuyt X.: Anti-PM/Scl 100 and anti-RNA-polymerase III antibodiesin scleroderma. Clin. Chim. Acta, 2010; 411: 965-971
  Google Scholar
• 12. Mahler M., Silverman E.D., Schulte-Pelkum J., Fritzler M.: AntiScl70(topo-1) antibodies in SLE: myth or reality? Autoimmun. Rev.,2010; 9: 756-760
  Google Scholar
• 13. Mahler M., You D., Baron M., Taillefer S.S., Hudson M.; CanadianScleroderma Research Group(CSRG), Fritzler M.J.: Anti-centromereantibodies in a large cohort of systemic sclerosis patients: comparisonbetween immunofluorescence; CENP-A and CENP-B ELISA. Clin.Chim. Acta, 2011; 412: 1937-1943
  Google Scholar
• 14. Medsger T.A.Jr., Bombardieri S., Czirjak L., Scorza R., Della RossaA., Bencivelli W.: Assessment of disease severity and prognosis. Clin.Exp. Rheumatol., 2003; 21: S42-S46
  Google Scholar
• 15. Muller Cde S., Paiva Edos S., Azevedo V.F., Radominski S.C., LimaFilho J.H.: Autoantibody profile and clinical correlation in a group ofpatients with systemic sclerosis in southern Brazil. Rev. Bras. Reumatol.,2011; 51: 314-318
  Google Scholar
• 16. Puszczewicz M., Białkowska-Puszczewicz G.: Platelet-derivedgrowth factor receptor antibodies in systemic sclerosis. Reumatologia,2006; 44: 281-284
  Google Scholar
• 17. Reveille J.D., Solomon D.H.: The American College of RheumatologyAd hoc Committee on Immunologic Testing Guidelines Evidencebasedguidelines for the use of immunologic tests anticentromere,Scl-70 and nucleoral antibodies. Arthritis Rheum., 2003; 49: 399-412
  Google Scholar
• 18. Satiago M., Baron M., Hudson M., Burlingame R.W., Fritzler M.J.:Antibodies to RNA polymerase III in systemic sclerosis as detectedby Elisa. J. Rheumatol., 2007; 34: 1528-1534
  Google Scholar
• 19. Shanmugam V.K., Swistowski D.R., Saddic N., Wang H., SteenV.D.: Comparison of indirect immunofluorescence and multiplexantinuclear antibodies screening in systemic sclerosis. Clin. Rheumatol.,2011; 30: 1363-1368
  Google Scholar
• 20. Tan E.N.: Antinuclear antibodies. Diagnostic markers for autoimmunediseases and probes for cell biology. Adv. Immunol., 1989;44: 93-151
  Google Scholar
• 21. Valentini G., Silman A.J., Veale D.: Assessment of disease activity.Clin. Exp. Rheumatol., 2003; 21: S39-S41
  Google Scholar
• 22. Walker J.G., Pope J., Baron M., Leclercq S., Hudson M., TailleferS., Edworthy S.M., Nadashkevich O., Fritzler M.J.: The developmentof systemic sclerosis classification criteria. Clin. Rheumatol., 2007;26: 1401-1409
  Google Scholar

Pełna treść artykułu